Solna, Sweden 24 January 2022 – Oasmia Pharmaceutical AB (Oasmia), an oncology-focused specialty pharmaceutical company, today announced progress on the in-house development of XR-18, the next generation of its proprietary drug delivery technology.
The Company has identified and synthesized a promising novel candidate for use in the
XR-18 drug delivery platform, which it believes could offer enhanced capabilities compared with its existing XR-17 technology. The XR-17 drug delivery platform is designed to increase the solubility of intravenously delivered compounds and has been used successfully in Oasmia’s ovarian cancer therapy Apealea®.
The next-generation formulation applied in XR-18 is already being tested in combination with a widely used oncology compound, and steps for securing Intellectual Property are being taken.
Reinhard Koenig, MD, Chief Science Officer, Oasmia, commented: “Oasmia’s growth strategy is centered on the in-licensing and acquisition of innovative oncology therapies alongside the in-house development of promising new treatments. With the in-licensing of Cantrixil for ovarian cancer in 2021 and encouraging progress in the development of XR-18, we are keeping our promise to both investors and patients. We believe XR-18 has the potential to offer enhanced delivery of current and future investigational drug candidates, and we look forward to updating the market on our progress.”
For More Information:
Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Consilium Strategic Communications
Jonathan Birt, Ashley Tapp
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.